Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Cellectar Biosciences, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −1 vs. Q2 2023
- Shares held
- 1.46M
- −139.8K (−8.7%) vs. Q2 2023
- Total value
- $3.85M
- +$772.3K (+25.1%) vs. Q2 2023
- New holders
- 4
- 6 more added
- Sold out
- 5
- 4 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLRB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 29 | $9.08M |
| Q1 2026 | 19 | $812.9K |
| Q4 2025 | 20 | $1.04M |
| Q3 2025 | 21 | $1.65M |
| Q2 2025 | 19 | $734.0K |
| Q1 2025 | 32 | $1.63M |
| Q4 2024 | 30 | $1.52M |
| Q3 2024 | 35 | $30.0M |
| Q2 2024 | 37 | $28.3M |
| Q1 2024 | 45 | $36.3M |
| Q4 2023 | 26 | $23.9M |
| Q3 2023 | 20 | $3.85M |
| Q2 2023 | 21 | $3.08M |
| Q1 2023 | 21 | $2.43M |
| Q4 2022 | 26 | $3.22M |
| Q3 2022 | 22 | $2.14M |
| Q2 2022 | 33 | $3.61M |
| Q1 2022 | 32 | $4.69M |
| Q4 2021 | 42 | $4.38M |
| Q3 2021 | 40 | $6.77M |
| Q2 2021 | 46 | $14.9M |
| Q1 2021 | 45 | $24.2M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Cellectar Biosciences, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 677,511 | $1.79M | 0.85% | −135,686−16.7% | Reduced |
| Worth Venture Partners, LLC | 279,123 | $736.9K | 0.44% | −34,386−11.0% | Reduced |
| Vanguard Group Inc | 175,884 | $464.3K | 0.00% | +3,911+2.3% | Added |
| Acuta Capital Partners, LLC | 121,300 | $320.2K | 0.23% | +121,300 | New |
| Geode Capital Management, LLC | 62,848 | $166.0K | 0.00% | +15,979+34.1% | Added |
| BlackRock Inc. | 57,042 | $150.6K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 21,690 | $57.0K | 0.00% | −42,300−66.1% | Reduced |
| State Street Corp | 15,714 | $41.5K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 15,000 | $39.6K | 0.00% | 00.0% | Unchanged |
| Commerce Bank | 12,000 | $31.7K | 0.00% | +12,000 | New |
| Wealth Enhancement Advisory Services, LLC | 12,000 | $31.7K | 0.00% | +12,000 | New |
| Tower Research Capital LLC (TRC) | 5,964 | $15.7K | 0.00% | +1,121+23.1% | Added |
| UBS Group AG | 1,256 | $3.32K | 0.00% | +56+4.7% | Added |
| Advisor Group Holdings, Inc. | 542 | $1.43K | 0.00% | +21+4.0% | Added |
| US Bancorp | 285 | $752 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 71 | $188 | 0.00% | +11+18.3% | Added |
| FMR LLC | 48 | $127 | 0.00% | −1−2.0% | Reduced |
| Harbour Investments, Inc. | 40 | $106 | 0.00% | 00.0% | Unchanged |
| AllSquare Wealth Management LLC | 18 | $48 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 11 | $29 | 0.00% | +11 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −30,790−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Monticello Wealth Management, LLC | 0 | $0 | 0.00% | −18,000−100.0% | Sold out |
| Altshuler Shaham Ltd | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Benjamin Edwards Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |